F10 and atrial fibrillation: At this point, these figures were determined as 2.1% for the intention to treat the population under the heading of stroke and systemic embolism in the ROCKET-AF study (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in AF), in which rivaroxaban was compared to warfarin [14].